Eisai Co (FRA:EIIA) Interest Expense (Positive)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:EIIA Eisai Co Ltd FRA:EIIA
80 GF Score
Price €6.35
GF Value €7.66
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Eisai Co Interest Expense (Positive)?

Interest Expense (Positive) only applies to insurance companies.

FRA:EIIA
80GF Score
Eisai Co Ltd FRA:EIIA
Interest Expense (Positive) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Eisai Co (FRA:EIIA) Overvalued in 2026?

Based on GuruFocus' analysis, Eisai Co stock appears to be undervalued. The current stock price of €6.35 is trading 17.1% below its estimated GF Value™ of €7.66. GuruFocus considers Eisai Co to be Modestly Undervalued.

Key valuation signals for FRA:EIIA:

  • Interest Expense (Positive):
  • GF Value™: €7.66 vs. price of €6.35 (17.1% below fair value)
  • GF Score™: 80/100 with 6 warning signs

No single metric tells the full story. See the FRA:EIIA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Eisai Co Business Description

Address 4-6-10 Koishikawa, Bunkyo-ku, Tokyo, JPN, 112-8088
Eisai Co., Ltd. is a Japanese pharmaceutical company focused on neurology and oncology, with additional franchises in gastrointestinal and other therapeutic areas. Its best-known products include lecanemab (Leqembi), developed with Biogen for Alzheimer's disease, and the anticancer agent lenvatinib (Lenvima), partnered with Merck. Eisai also markets proton pump inhibitors and other medicines, and operates a consumer healthcare business in Japan. The company conducts research, development, manufacturing, and sales through subsidiaries and partners worldwide, organized around regions including Japan, the Americas, Europe, the Middle East, Africa, Russia, Oceania, China, and broader Asia. Revenue comes from prescription drug sales, licensing and collaboration arrangements, and consumer products, with North America and Japan among its largest markets. Eisai emphasizes its human health care philosophy and reinvests heavily in research and development.
80GF Score

Get the complete analysis for FRA:EIIA

Interest Expense (Positive) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.35
Price
€7.66
GF Value